Bridging and Downstaging Data
TheraSphere Y-90 Glass Microspheres may be an option supporting Bridging or Downstaging Hepatocellular Carcinoma (HCC) to Liver Transplant therapy. Data shows 47% of T2+ patients were downstaged to <T2, and 58% of T3 patients were downstaged to T2, compared to 31% with TACE. TheraSphere demonstrated strong local tumor control and high rates of Complete Pathologic Necrosis. It also preserved a high percentage of patients within the Milan criteria for transplant and showed strong Overall Survival outcomes. In total, 169 patients were bridged and 38 patients were downstaged for liver transplant.